Horizon Therapeutics Plc - HZNP STOCK NEWS

Horizon Therapeutics has partnered with the Doug the Pug Foundation and Sing Me A Story Foundation to launch the #RAREis Playlist program, focusing on children with rare diseases. The initiative aims to amplify their voices through storytelling and music. Leanor, a 7-year-old with Ewing sarcoma, inspired a new song titled 'The Quest for the Golden Pearl'. The music video will premiere on February 17, followed by a social media challenge on February 20. This program has evolved since 2017 to provide resources for families navigating rare diseases.

Horizon Therapeutics has secured a six-year Title Partnership with the Irish Open, kicking off with the 2022 event at Mount Juliet Estate from June 30 to July 3. This partnership underscores Horizon's commitment to the Irish community, where it has operated for nearly a decade. The company has also committed approximately €1,000,000 to community support, including scholarships for disadvantaged students. The partnership aims to enhance Horizon's brand visibility while positively impacting both local and global communities.

Horizon Therapeutics plc (Nasdaq: HZNP) is set to announce its fourth-quarter and full-year 2021 financial results on March 1, 2022, at 8 a.m. Eastern Time. Following this, the management will host a live webcast to discuss the financial and operational outcomes. Interested parties can access the live webcast and replay via the company’s investor relations website. Horizon focuses on developing therapies for rare, autoimmune, and severe inflammatory diseases, aiming to address critical patient needs.

Horizon Therapeutics plc (Nasdaq: HZNP) has initiated its Phase 2b pivotal trial for HZN-825, a treatment targeting idiopathic pulmonary fibrosis (IPF). This progressive lung disease affects 100,000 people in the U.S., with a median survival of under five years. The trial will enroll approximately 360 patients to evaluate the safety, efficacy, and tolerability of HZN-825, focusing on lung capacity changes over 52 weeks. Encouraging results from previous Phase 2a trials suggest potential benefits in fibrosis and inflammation.

On January 11, 2022, ACELYRIN, INC. appointed Melanie Gloria as the new Chief Operating Officer (COO). With over 20 years in biotechnology, Gloria previously held senior roles at Abbott, AbbVie, and Horizon Therapeutics, leading R&D functions and achieving global therapy approvals. Her extensive background in drug development includes multiple therapeutic areas such as oncology and immunology. The leadership team believes Gloria's experience will enhance ACELYRIN's pursuit of life-changing treatments and support its growth strategy.

Horizon Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the FDA for KRYSTEXXA plus methotrexate, aimed at expanding its usage for uncontrolled gout. This decision follows the positive 71% response rate from the MIRROR randomized clinical trial. The combination therapy aims to improve efficacy by decreasing anti-drug antibodies. The sBLA submission also reflects a shift in uncontrolled gout treatment since 2018. The FDA is expected to complete its review in the second half of 2022.

Horizon Therapeutics (NASDAQ: HZNP) has signed a long-term lease for a 192,000-square-foot facility in Rockville, Maryland, marking a significant expansion of its East Coast operations. The new center will be dedicated to research, development, and technical operations, quadrupling Horizon's existing Maryland footprint. Construction is underway, with interior improvements expected to begin in 2023. This strategic move aims to enhance Horizon's capabilities in developing treatments for rare and autoimmune diseases while contributing to job growth in the local biotechnology sector.

Horizon Therapeutics plc (Nasdaq: HZNP) will participate in two upcoming virtual investor conferences. Tim Walbert, CEO, will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 9 a.m. ET. Additionally, at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, Walbert and Elizabeth H.Z. Thompson, EVP of Research and Development, will present at 11:15 a.m. ET. Both presentations will be webcast live on Horizon's website, with replays available after.

Horizon Therapeutics and Alpine Immune Sciences have announced an exclusive licensing agreement for the development of up to four preclinical candidates. Horizon will pay $40 million upfront, with the potential for Alpine to earn up to $1.52 billion in milestone and royalty payments. The collaboration aims to merge Alpine's discovery platform with Horizon's development capabilities, particularly for autoimmune and inflammatory diseases. This partnership marks a significant expansion of Horizon's preclinical pipeline.